A New Rabbit Monoclonal E-cadherin Antibody (EP700Y) Shows Higher Sensitivity than Mouse Monoclonal E-cadherin (HECD-1) Antibody in Infiltrating Ductal Carcinomas

Modern Pathology 2013; 26, Supplement 2: 46A. Introduction Infiltrating ductal carcinoma is the most common histologic phenotype of breast cancer, comprising 70% to 80% of all cases. The diagnostic distinction between ductal carcinoma in situ and lobular carcinoma in situ of the breast is critical in therapeutic planning. The treatment for ductal carcinoma in situ typically focuses on eradication of the lesion, requiring an accurate assessment of tumor margins, followed by radiation therapy1. Lobular carcinoma in situ, however, is considered to put the patient at increased risk for future invasive disease and it is typically not treated surgically. This difference in treatment strategy requires accurate discrimination between lesions of ductal carcinoma in situ and lobular carcinoma in situ.